Glenmark Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
6204.42
Cr.
PAT
610.43
Cr.
EBITDA
2418.98
Cr.
Glenmark Pharmaceuticals Ltd. Q1FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 6003.79 | 3059.33 | 3220.13 | 3301.90 | 3400.50 |
| Total Income From Operations (Cr.) | 6046.87 | 3264.44 | 3256.21 | 3387.55 | 3433.80 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 2418.98 | 477.04 | 447.51 | 508.62 | 521.05 |
| P/L Before Exceptional Items & Tax (Cr.) | 2352.52 | 418.81 | 380.79 | 456.33 | 472.57 |
| P/L After Tax from Ordinary Activities (Cr.) | 610.43 | 46.97 | 4.38 | 348.03 | 354.49 |
| Net Profit/Loss For the Period (Cr.) | 610.43 | 46.97 | 4.38 | 348.03 | 354.49 |
| Basic EPS | 21.63 | 1.66 | 0.16 | 12.33 | 12.55 |
FAQs
Glenmark Pharmaceuticals Ltd. announced its quarterly results for Q1 FY2026 on August 14, 2025.
In Q1 FY2026, Glenmark Pharmaceuticals Ltd. are as follows:
Revenue: ₹6204.42 crore
Net Profit: ₹610.43 crore.
For Q1 FY2026, Glenmark Pharmaceuticals Ltd. posted ₹6204.42 crore in revenue and ₹610.43 crore in net profit.
Past quarterly results for Glenmark Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.